The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities
Open accessAbstract
Cell surface glycosylation is dynamic and often changes in response to cellular differentiation under physiological or pathophysiological conditions. Altered glycosylation on cancers cells is gaining attention due its wide-spread occurrence across a variety of cancer types and recent studies that have documented functional roles for aberrant glycosylation in driving cancer progression at various stages. One change in glycosylation that can correlate with cancer stage and disease prognosis is hypersialylation. Increased levels of sialic acid are pervasive in cancer and a growing body of evidence demonstrates how hypersialylation is advantageous to cancer cells, particularly from the perspective of modulating immune cell responses. Sialic acid-binding receptors, such as Siglecs and Selectins, are well-positioned to be exploited by cancer hypersialylation. Evidence is also mounting that Siglecs modulate key immune cell types in the tumor microenvironment, particularly those responsible for maintaining the appropriate inflammatory environment. From these studies have come new and innovative ways to block the effects of hypersialylation by directly reducing sialic acid on cancer cells or blocking interactions between sialic acid and Siglecs or Selectins. Here we review recent works examining how cancer cells become hypersialylated, how hypersialylation benefits cancer cells and tumors, and proposed therapies to abrogate hypersialylation of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Siglec-mediated regulation of immune cell function in disease
Macauley, M. S., Crocker, P. R., & Paulson, J. C. (2014) · Nature Reviews Immunology · doi:10.1038/nri3737 · Cited by 1,122
Self-citationLau, K. S., Partridge, E. A., Grigorian, A., Silvescu, C. I., Reinhold, V. N., Demetriou, M., & Dennis, J. W. (2007) · Cell · doi:10.1016/j.cell.2007.01.049 · Cited by 914 · cited 1×
“branching that provides more acceptor sites for sialylation [77].”
BackgroundSialic acids in cancer biology and immunity
Pearce, O. M. T., & Läubli, H. (2016) · Glycobiology · doi:10.1093/glycob/cwv097 · Cited by 470 · cited 1×
“Indeed, a growing body of evidence demonstrates that cancer cells have significantly elevated levels of sialic acid compared to non-transformed cells [6] (Figure 1).”
BackgroundCarlin, A. F., Uchiyama, S., Chang, Y.-C., Lewis, A. L., Nizet, V., & Varki, A. (2009) · Blood · doi:10.1182/blood-2008-11-187302 · Cited by 401 · cited 1×
“Careful inspection of the data using the only commercially available anti-Siglec-9 ligand-blocking antibody, however, suggests that this antibody may itself activate myeloid cells expressing Siglec-9 [32,113,133].”
BackgroundInduction of myelodysplasia by myeloid-derived suppressor cells
Chen, X., Eksioglu, E. A., Zhou, J., Zhang, L., Djeu, J., Fortenbery, N., Epling-Burnette, P., Van Bijnen, S., Dolstra, H., Cannon, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67580 · Cited by 316 · cited 1×
“, IL-10 production) of MDSCs, which was suggested to take place through abrogating TLR4 signaling [117] (Figure 2e).”
BackgroundStructural basis for sialic acid–mediated self-recognition by complement factor H
Blaum, B. S., Hannan, J. P., Herbert, A. P., Kavanagh, D., Uhrín, D., & Stehle, T. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1696 · Cited by 278
Sialic Acid Mimetics to Target the Sialic Acid–Siglec Axis
Büll, C., Heise, T., Adema, G. J., & Boltje, T. J. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.03.007 · Cited by 165
Systemic Blockade of Sialylation in Mice with a Global Inhibitor of Sialyltransferases
Macauley, M. S., Arlian, B. M., Rillahan, C. D., Pang, P.-C., Bortell, N., Marcondes, M. C. G., Haslam, S. M., Dell, A., & Paulson, J. C. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.606517 · Cited by 129 · cited 1×
“However, due to the multi-facetted physiological roles of sialic acid, it was revealed that while 3F-Neu5Ac is extremely effective in vivo, it produces kidney dysfunction due to specific removal of sialic acid residues from podocytes, thus destroying glomerular filtration in the kidney [144].”
BackgroundSelf-citation
Cited by
Harnessing innate immunity in cancer therapy
Demaria, O., Cornen, S., Daëron, M., Morel, Y., Medzhitov, R., & Vivier, E. (2019) · Nature · doi:10.1038/s41586-019-1593-5 · Cited by 957
Insights into the role of sialylation in cancer progression and metastasis
Dobie, C., & Skropeta, D. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01126-7 · Cited by 348
Rodriguez, E., Boelaars, K., Brown, K., Eveline Li, R. J., Kruijssen, L., Bruijns, S. C. M., van Ee, T., Schetters, S. T. T., Crommentuijn, M. H. W., van der Horst, J. C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21550-4 · Cited by 311
Altered Cell Adhesion and Glycosylation Promote Cancer Immune Suppression and Metastasis
Läubli, H., & Borsig, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02120 · Cited by 282
Hassinen, A., Khoder-Agha, F., Khosrowabadi, E., Mennerich, D., Harrus, D., Noel, M., Dimova, E. Y., Glumoff, T., Harduin-Lepers, A., Kietzmann, T., et al. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101182 · Cited by 33
“Sialylation regulates numerous cellular processes, including cell–cell communication, immune surveillance, defense against pathogens and cancer progression and metastasis [46,53].”
Background
Metadata
- Authors
- Rodrigues, E., & Macauley, M.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2018-06-18
- Volume
- 10
- Issue
- 6
- Pages
- 207
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2807859574
- Cited by
- 240
- References
- 9
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities. https://app.cochat.ai/papers/10.3390/cancers10060207
- The paper
- Rodrigues, E., & Macauley, M. (2018). Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities. Cancers. https://doi.org/10.3390/cancers10060207
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.